230 related articles for article (PubMed ID: 22678691)
1. Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms.
Ferrero S; Drandi D; Mantoan B; Ghione P; Omedè P; Ladetto M
Hematol Oncol; 2011 Dec; 29(4):167-76. PubMed ID: 22678691
[TBL] [Abstract][Full Text] [Related]
2. Molecular methods for detection of minimal residual disease following transplantation in lymphoid and plasma cell disorders.
Corradini P; Carniti C
Methods Mol Biol; 2014; 1109():209-37. PubMed ID: 24473786
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease detection in mantle cell lymphoma: technical aspects and clinical relevance.
Pott C
Semin Hematol; 2011 Jul; 48(3):172-84. PubMed ID: 21782059
[TBL] [Abstract][Full Text] [Related]
4. Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.
Drandi D; Kubiczkova-Besse L; Ferrero S; Dani N; Passera R; Mantoan B; Gambella M; Monitillo L; Saraci E; Ghione P; Genuardi E; Barbero D; Omedè P; Barberio D; Hajek R; Vitolo U; Palumbo A; Cortelazzo S; Boccadoro M; Inghirami G; Ladetto M
J Mol Diagn; 2015 Nov; 17(6):652-60. PubMed ID: 26319783
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma.
Lobetti-Bodoni C; Mantoan B; Monitillo L; Genuardi E; Drandi D; Barbero D; Bernocco E; Boccadoro M; Ladetto M
Ther Adv Hematol; 2013 Jun; 4(3):189-98. PubMed ID: 23730496
[TBL] [Abstract][Full Text] [Related]
6. Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle.
Brüggemann M; Gökbuget N; Kneba M
Semin Oncol; 2012 Feb; 39(1):47-57. PubMed ID: 22289491
[TBL] [Abstract][Full Text] [Related]
7. [Minimal residual disease in follicular and mantle cell lymphoma. Detection using quantitative molecular monitoring of circulating lymphoma cells].
Schüler F; Hirt C; Dölken L; Krüger W; Dölken G
Dtsch Med Wochenschr; 2005 Sep; 130(38):2130-4. PubMed ID: 16172952
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of flow cytometric immunophenotypic analysis for minimal residual disease detection in autologous stem-cell products of follicular and mantle cell lymphomas.
Kato H; Yamamoto K; Oki Y; Ine S; Taji H; Chihara D; Kagami Y; Seto M; Morishima Y
Leukemia; 2012 Jan; 26(1):166-9. PubMed ID: 21818114
[No Abstract] [Full Text] [Related]
9. Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders.
Drandi D; Ferrero S; Ladetto M
Methods Mol Biol; 2018; 1768():229-256. PubMed ID: 29717447
[TBL] [Abstract][Full Text] [Related]
10. Detection of minimal residual disease in acute leukemia.
van der Velden VH; Boeckx N; van Wering ER; van Dongen JJ
J Biol Regul Homeost Agents; 2004; 18(2):146-54. PubMed ID: 15471219
[TBL] [Abstract][Full Text] [Related]
11. Molecular and clinical follow-up after treatment of multiple myeloma.
Rasmussen T; Knudsen LM; Huynh TK; Johnsen HE
Acta Haematol; 2004; 112(1-2):105-10. PubMed ID: 15179010
[TBL] [Abstract][Full Text] [Related]
12. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies.
Moos M; Schulz R; Cremer F; Sucker C; Schmohl D; Döhner H; Goldschmidt H; Haas R; Hunstein W
Stem Cells; 1995 Dec; 13 Suppl 3():42-51. PubMed ID: 8747988
[TBL] [Abstract][Full Text] [Related]
13. [Use of polymerase chain reaction (PCR) in oncohematology. Detection of minimal residual disease].
Kotliar N; Koziner B
Medicina (B Aires); 1995; 55(2):159-66. PubMed ID: 7565055
[TBL] [Abstract][Full Text] [Related]
14. Quantitative assessment of minimal residual disease (MRD) in canine lymphoma by using real-time polymerase chain reaction.
Yamazaki J; Baba K; Goto-Koshino Y; Setoguchi-Mukai A; Fujino Y; Ohno K; Tsujimoto H
Vet Immunol Immunopathol; 2008 Dec; 126(3-4):321-31. PubMed ID: 18977540
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease as a surrogate marker for risk assignment to ALL patients.
Cazzaniga G; Gaipa G; Rossi V; Biondi A
Rev Clin Exp Hematol; 2003 Sep; 7(3):292-323. PubMed ID: 15024971
[TBL] [Abstract][Full Text] [Related]
16. [Chronic lymphoproliferative disorders].
Salles G
Rev Prat; 2002 May; 52(9):966-71. PubMed ID: 12063762
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease monitoring: the new standard for treatment evaluation of haematological malignancies?
Hauwel M; Matthes T
Swiss Med Wkly; 2014 Jan; 144():w13907. PubMed ID: 24452390
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L
Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
[TBL] [Abstract][Full Text] [Related]
19. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma.
Fenk R; Ak M; Kobbe G; Steidl U; Arnold C; Korthals M; Hünerlitürkoglu A; Rohr UP; Kliszewski S; Bernhardt A; Haas R; Kronenwett R
Haematologica; 2004 May; 89(5):557-66. PubMed ID: 15136219
[TBL] [Abstract][Full Text] [Related]
20. Detection of minimal residual disease in peripheral blood prior to clinical relapse of childhood acute lymphoblastic leukaemia using PCR.
Lal A; Kwan E; Haber M; Norris MD; Marshall GM
Mol Cell Probes; 2001 Apr; 15(2):99-103. PubMed ID: 11292328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]